M

Multiply Labs

Robotic biomanufacturing infrastructure for cell therapies

Head of Product

Full-TimePosted on 10/21/2026
$220k - $290k/yr+ Early-stage equity + 4% 401(k) match + Referral bonuses
Expert
Bachelor's, Master's
San Francisco, CA, USA
In PersonSome roles may require 5–10% domestic and international travel.
ProductProduct Management
H1B Sponsorship Available

About the job

Requirements
  • At least 8 years of product management experience, including at least 3 years directly managing and scaling a team of Product Managers.
  • Proven track record leading complex hardware-software products involving robotics and electromechanical systems.
  • Demonstrated success taking complex technical products from concept through deployment and commercial scale.
  • Bachelor’s or Master’s degree in Engineering, Computer Science, Robotics, or a related field.
  • Hands-on proficiency with project and product management frameworks and tools such as JIRA, Asana, and SmartSheets.
  • Occasional use of personal protective equipment, including a lab coat, safety glasses, and gloves, for customer site visits and deployment walk-throughs.
  • Standard full-time schedule, with occasional evening and weekend flexibility required around critical customer deployments.
Responsibilities
  • Define, communicate, and execute the long-term product strategy and roadmap for automated advanced biologics manufacturing systems, aligning platform development with key commercial milestones.
  • Partner with the CEO and hardware, software, bioprocess, and quality leadership to drive a cohesive product vision, architecture, and product requirements.
  • Hire, mentor, and scale high-performing product and biosciences teams.
  • Oversee the Biosciences team in defining biological product requirements, executing internal cell testing, partnering directly with pharmaceutical customers to analyze pilot data, and demonstrating process comparability.
  • Make prioritization tradeoffs among custom customer requirements, core platform standardization, and ongoing engineering improvements.
  • Serve as the primary product partner to executive leadership and cross-functional teams at major pharmaceutical client accounts, translating customer goals and needs into actionable product requirements.
  • Collaborate with Business Development, Strategic Alliance Management, Supply Chain, and Engineering to ensure product readiness for customer deployments and platform launches.
  • Drive systematic customer discovery, market analysis, and user interviews across the biopharma landscape to identify unmet clinical manufacturing needs and emerging industry trends.
Desired Qualifications
  • Prior experience within biotech, medical devices, automotive, aerospace, or other regulated development environments.
  • Track record of scaling a product organization through early commercialization at a high-growth, venture-backed company.
  • Experience navigating joint development milestones, pilots, and acceptance criteria with customers and partners.
  • Familiarity with advanced therapy manufacturing, including cell and gene therapies and antibodies, or bioprocess development.
  • Experience incorporating computer vision, machine learning, or artificial intelligence capabilities into products.

About the company

Multiply Labs builds robotic biomanufacturing infrastructure for cell and gene therapies and advanced biologics. Its modular Cluster automates workflows by integrating existing GMP instruments in a closed system and learning processes through imitation learning rather than full process transfer. Digital QC software monitors real-time sensors and generates 21 CFR Part 11–compliant electronic batch records. The company partners with pharma and research institutions to expand scalable, compliant manufacturing capacity and accelerate commercial-scale product development.

Company Size

51-200

Company Stage

Series B

Total Funding

$98M

Headquarters

San Francisco, California

Founded

2016

Get referred to Multiply Labs

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 raised $75 million to expand capacity and accelerate commercial-scale product development.
  • May 14, 2024 Retro Biosciences deal became Multiply Labs' first commercial robotic system sale.
  • January 27, 2026 AstraZeneca and existing partners expand credibility with top-tier pharma buyers.

What critics are saying

  • Cellares, Thermo Fisher, Cytiva, and Sartorius already crowd the same automation budget.
  • May 2026 Italy subsidiary still lacks disclosed capacity plans, timelines, and customer commitments.
  • If AstraZeneca and Retro pilots stall, Multiply Labs stays a capital-intensive demo vendor.

What makes Multiply Labs unique

  • Multiply Labs' January 27, 2026 AstraZeneca collaboration validates GMP-ready robotic cell-therapy automation.
  • May 27, 2026 Italy subsidiary and Enrico Racca show manufacturing-first scaling discipline.
  • September 2026 Series B investors include AstraZeneca Ventures, Legend Biotech, and Founders Fund.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Work from home option

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

4%
HyperAI
Oct 6th, 2026
Multiply Labs raises $75 million to automate drug manufacturing.

Multiply Labs raises $75 million to automate drug manufacturing. Multiply Labs, a San Francisco based robotics startup, announced Tuesday the closing of a $75 million Series B funding round aimed at automating the manufacturing of complex biologics and gene therapies. The round, led by NantWorks, the holding company founded by billionaire Patrick Soon Shiong, also includes investments from AstraZeneca, Lux Capital, and Founders Fund. With this capital injection, the company has surpassed $100 million in total funding since its 2016 founding. Multiply Labs operates at the intersection of artificial intelligence and advanced manufacturing, addressing a critical bottleneck in modern pharmaceutical production. While computational models can accelerate drug discovery, the physical fabrication of advanced therapies remains largely manual, labor intensive, and highly susceptible to contamination. According to a 2025 industry analysis, producing a single dose of certain gene therapies can exceed one million dollars. Multiply Labs counters this inefficiency by deploying integrated robotic systems designed to standardize and scale the synthesis of mRNA treatments and cell based therapies. Chief Executive Fred Parietti emphasized that automated production is the only viable path to achieving consistent throughput, quality control, and economic feasibility. The company machines currently reside in specialized warehouse facilities, featuring compact robotic arms and fluid handling modules optimized for closed system processing. Multiply Labs generates revenue through direct equipment sales to pharmaceutical partners, recurring income from proprietary reaction cartridges, and ongoing technical support. While executive leadership declined to disclose exact deployment figures, the current installed base remains in the high single digits. The funding will primarily focus on refining manufacturing workflows, expanding the European supply chain for critical components, and scaling operations to transition from early adopter pilots to broader commercial production. Pharma manufacturers such as AstraZeneca and Legend Biotech are already operating the systems in house, providing real world validation before widespread industry adoption. This capital raise aligns with a broader market shift toward physical AI, where machine learning and robotics converge to automate physical processes previously confined to human dominated laboratories. Investors are increasingly capitalizing on platforms that translate digital intelligence into tangible manufacturing outputs. Multiply Labs immediate challenge lies in reducing per unit costs from multi million dollar capital expenditures to car priced equipment, while simultaneously streamlining maintenance and supply logistics. Success in this transition would effectively decouple advanced drug production from manual laboratory constraints, establishing a new standard for scalable, cost effective biomanufacturing.

Business Insider
Oct 6th, 2026
Robotics startup Multiply Labs raises $75M to automate drug manufacturing

Multiply Labs, a San Francisco robotics startup automating drug manufacturing, raised $75 million in Series B funding led by NantWorks. The round brings total funding to over $100 million since 2016. The company builds robots that manufacture complex drugs like gene therapies and mRNA treatments, which are typically made manually in laboratories. Production costs for some gene therapies exceed $1 million per dose, according to 2025 research. Multiply's robots currently cost several million dollars each to build. Drugmakers including AstraZeneca and Legend Biotech purchase and operate the machines at their facilities. Multiply also generates revenue from cartridges and service support. The company has deployed a high single-digit number of machines with customers. CEO Fred Parietti said robotics is essential to achieve necessary throughput, cost reduction, and quality in drug manufacturing.

Tracxn
Apr 6th, 2026
Multiply Labs - Funding & investors.

Multiply Labs - Funding & investors. Last updated: April 6, 2026 Multiply Labs' funding rounds. Multiply Labs has raised a total of $41.3M over 7 funding rounds: 3 Seed and 4 Early-Stage round s. Multiply Labs' largest funding round so far was a Series A round for $***** in Apr 2021. Here is the list of all funding rounds of Multiply Labs: | Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors | | Apr 21, 2023 | 2041367 | Series A | 3319109 | 9135293 | 3099539 | 4086360 | | Apr 14, 2021 | 2657263 | Series A | 5925816 | 4466755 | 6608485 | Lux Capital & 3 more | | Oct 27, 2018 | 9572761 | Series A | 4644887 | 9212511 | 8077938 | 2014680 | | May 11, 2017 | 4797781 | Series A | 3875885 | 9861974 | 3348546 | Graph Ventures & 5 more | | 2016 | 3338 | Seed | 8966 | 6394 | MIT Sandbox Innovation Fund Program | 1984 | | Aug 22, 2016 | 6270815 | 275706 | 1251781 | 3745093 | 8161543 | 4582795 | | Aug 20, 2016 | 6353672 | 624806 | 7882936 | 5171611 | 9475670 | 8336843 | Multiply Labs' investors. Multiply Labs has total 24 investor s, 24 are institutional investors including Y Combinator and 23 others. Here is the list of institutional investors of Multiply Labs: * Lux Capital, located in Menlo Park (United States), made their first investment in Multiply Labs on Apr 14, 2021 in its Series A round. * Graph Ventures, located in San Francisco (United States), made their first investment in Multiply Labs on May 11, 2017 in its Series A round. * MIT Sandbox Innovation Fund Program, located in Cambridge (United States), made their first investment in Multiply Labs on 2016 in its Seed round. Are you a Founder? FAQs about Multiply Labs' funding and investors. Multiply Labs has raised a total of $41.3M over 7 rounds. Multiply Labs' largest funding round was a Series A round held on Apr 14, 2021 for $*****. * 4 Early-Stage rounds * 3 Seed rounds Multiply Labs has a total of 24 investors, all of them are Institutional investors. Explore latest companies that raised funding recently * Budderfly - Shelton based, raised a funding of $100M in Conventional Debt round held on Jun 23, 2025. * Vizsla Silver - Vancouver based, raised a funding of $100M in Post IPO round held on Jun 23, 2025. * PhysicsX - London based, raised a funding of $135M in Series B round held on Jun 23, 2025. * Techarena - raised a funding of $1.24M in Seed round held on Jun 23, 2025. * Tattle - New York City based, raised a funding of $1.5M in Venture Debt round held on Jun 23, 2025.

Business Wire
Jan 27th, 2026
Multiply Labs partners with AstraZeneca to automate cell therapy manufacturing with robotics

Multiply Labs has announced an agreement with AstraZeneca to evaluate GMP-ready robotic systems for commercial-scale cell therapy manufacturing. The collaboration will focus on end-to-end robotic automation of industry-standard instruments using Multiply Labs' biomanufacturing platform. The San Francisco-based robotics company develops autonomous manufacturing technology for advanced therapies. Its newest systems use four robotic arms operating in parallel to run cell therapy manufacturing instruments, aiming to maximise output whilst minimising process modifications. "Cell therapies are among the most promising, yet complex medicines being developed today," said Fred Parietti, CEO of Multiply Labs. "Our mission is to make these therapies more widely available by increasing manufacturing efficiency and scale." The collaboration seeks to enable scalable, high-throughput manufacturing whilst maintaining quality and regulatory standards for clinical and commercial use.

StockTitan
Sep 24th, 2024
Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Multiply Labs, a robotics company specializing in automated manufacturing systems for individualized drugs, has announced a collaboration with Legend Biotech (NASDAQ: LEGN).